Paolo Tarantino: Phase 1 trial of the HER2 topo1 ADC SHR-A1811 out in Journal of Clinical Oncology

Paolo Tarantino shared on X:  .

“Phase 1 trial of the HER2 topo1 ADC SHR-A1811 out in Journal of Clinical Oncology. Impressive activity among pts with HER2+ (ORR 76%, left) and HER2-low (ORR 60%, right) MBC, & in multiple other tumor types. ILD: 2.6%, 13 deaths due to AEs (4.2%), 4 treatment-related (1.3%).”

Raffaele Colombo replied to the tweet, adding the following:

“Identical mAb and linker, slightly different payload and DAR!”

Read further.
Source: Paolo Tarantino/X and Raffaele Colombo/X

Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer.

Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.

With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.

Raffaele Colombo, a leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.